

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CF PharmTech, Inc.
長風藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2652)

VOLUNTARY ANNOUNCEMENT

**SELECTION OF A COMPANY-LED PROJECT INTO THE
2025 JIANGSU PROVINCIAL
MAJOR SCIENCE AND TECHNOLOGY PROGRAM
“INNOVATIVE BIOLOGICS”**

This announcement is made by CF PharmTech, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide shareholders and potential investors with an update on the Group’s research and development progress.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the project on the development of novel inhalable nucleic acid drug (the “**Project**”), led by the Company, has recently been selected for the 2025 Jiangsu Provincial Major Science and Technology Program — “Innovative Biologics” (2025年江蘇省科技重大專項「創新生物藥」項目).

PROJECT DETAILS AND DEVELOPMENT

The Project focuses on key challenges in pulmonary delivery of small interfering RNA (“**siRNA**”) therapeutics, with the goal of advancing the translational and preclinical development of inhalable nucleic acid drug candidates.

The Project aims to support key research and development work for inhalable nucleic acid drug candidates targeting major respiratory diseases, including asthma, chronic obstructive pulmonary disease, and pulmonary fibrosis. The scope of work encompasses the optimization of delivery systems, pharmaceutical and process development, preclinical studies, and preparation for investigational new drug applications.

STRATEGIC SIGNIFICANCE

The Company believes that the selection of the Project is of significant strategic importance to the Group and further validates the strength of the Group's technology platform. Delivery technology represents a key barrier in siRNA lung treatment. In this regard, the Company has independently developed an efficient lung-targeted delivery system, with related drug candidates demonstrating promising therapeutic potential in preclinical studies. The selection of the Project reflects the full recognition by relevant authorities and review experts of the joint research and development capabilities of the Company and its partners in the field of cutting-edge delivery technology. The Company will continue to pursue technical innovation, aiming to provide more valuable treatment solutions for patients and create sustainable long-term returns for shareholders.

RISK WARNING

Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products, there are substantial risks and uncertainties in the process of drug research, development and commercialization. These many stages make it susceptible to uncertainties and therefore, shareholders and potential investors are advised to make cautious decisions and pay careful attention to investment risks.

By order of the Board
CF PharmTech, Inc.
長風藥業股份有限公司
Dr. LIANG Bill Wenqing
*Chairperson, Executive Director and
Chief Executive Officer*

Hong Kong, December 24, 2025

As at the date of this announcement, the Board comprises Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi and Ms. ZHU Yuyu as executive Directors, Mr. CHEN Penghui, Mr. CAI Lei and Dr. YI Hua as non-executive Directors, and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.